Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus PREDSULFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVELTYS versus PREDSULFAIR.
INVELTYS vs PREDSULFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
PREDSULFAIR is a combination of prednisolone (corticosteroid) and sulfacetamide (sulfonamide antibiotic). Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
Prednisolone 0.5-1 mg/kg orally once daily, maximum 60 mg/day; Sulfasalazine 500 mg orally twice daily, increased by 500 mg weekly to maintenance 2-3 g/day in divided doses.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
Prednisolone: 2.1–3.5 hours (plasma); biological half-life 12–36 hours (duration of HPA axis suppression). Sulfafurazole: 3–6 hours (normal renal function), prolonged to 12–24 hours in renal impairment.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
PREDSULFAIR is a fixed-dose combination of prednisolone and sulfafurazole. Prednisolone is primarily metabolized hepatically; inactive metabolites are excreted renally (<30% unchanged). Sulfafurazole is acetylated and glucuronidated; parent drug and metabolites are excreted renally (≥90%, with 15-30% unchanged). Biliary/fecal elimination is minimal for both components (<5%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination